In Intra Cellular Therapies v. Controller of Patents, the Delhi High Court examined critical issues related to disclosure and therapeutic efficacy standards under Indian patent law, impacting pharmaceutical patent evaluations.
Delhi High Court Addresses Disclosure and Efficacy in Patent Law
The Delhi High Court's decision in Intra Cellular Therapies v. Controller of Patents revisits key themes in pharmaceutical patent law, specifically focusing on disclosure requirements and the therapeutic efficacy standard as outlined in Section 3(d). This ruling brings clarity to the often contentious evaluation of patent applications in the pharmaceutical sector.
The court's analysis highlighted that while it correctly upheld some disclosures related to efficacy, it faced criticism for conflating coverage with disclosure. This raised issues about the existing standards of novelty and the application of the inventive step in determining patentability, which are critical to pharma companies seeking to secure and enforce patent rights in India.
The implications of this ruling are significant for practitioners in the pharmaceutical industry. Legal advisors must now be acutely aware of the stringent disclosure obligations that may affect patent applications, particularly concerning proving therapeutic efficacy according to the standards set forth in Section 3(d).
As this area of law continues to evolve, practitioners should be ready to adjust their strategies regarding patent applications and anticipate greater scrutiny from regulating bodies regarding disclosure and efficacy claims.
Citations
- Intra Cellular Therapies v. Controller of Patents (2026) Delhi HC
